Pharma news

Reset all filters
Geography
Company
Refine search
Indivior parts with $30m in Suboxone dispute
Pharma
The pharmaceutical company agreed to pay millions to resolve a multi-district antitrust suit brought by more than 40 US state attorneys | Company sued over alleged actions aimed at preserving the monopoly of anti-addiction drug.   22 August 2023
UPC confirms dates for 10x Genomics hearings
Pharma
UPC announces public hearings at Munich court | Proceedings relate to the dispute over patents covering the in-situ detection of analytes.   22 August 2023
Axonics v Medtronic: Fed Circ addresses PTAB ‘errors’
Americas
A recent precedential case highlights the thorny issue of what constitutes a fair response to new claim constructions following an institution, says Blair Jacobs of McKool Smith.   17 August 2023
Pharma
This week marks the first anniversary of its enactment but the US Inflation Reduction Act still poses questions for pharmaceutical companies, say Alice Valder Curran and Cullen Taylor of Hogan Lovells.   15 August 2023
Pharma
Are we now seeing the power posed by the court as a litigation forum, asks Antje Brambrink of Finnegan.   15 August 2023
Pharma
Patent-in-suit relates to a synthetic drug used to treat nicotine dependence | Development comes after USFood and Drug Administration sets new guidelines forcing the withdrawal of another big pharma firm’s rival drug.   10 August 2023
Pharma
US Court of Appeals highlights procedural rules in patent dispute concerning medical device charging patents | Medtronic now faces further patent validity reviews after Fed Circ rules in favour of rival.   8 August 2023
Pharma
GSK argues that its US rival knew of its patented technology seven years after research began | Blockbuster respiratory vaccines, world’s first of their kind, received US approval in May.   7 August 2023
Pharma
Joint stipulations approved by federal judge to dismiss three lawsuits alleging patent infringement on cancer immunotherapies | Companies settle early ‘to save time and attention’ say reports.   3 August 2023
Pharma
A reticent patent office and complex legal picture make getting IP protection of treatments based on the lucrative plant tricky, explain Priscila Kashiwabara and Luan Scalzitti of Kasznar Leonardos.   3 August 2023